focus -WSS

focus

author：leisure time 2025-09-11 15:33:39 - browse：979

Gilead office remdesivir — Yichuan Cao/Sipa USA

Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new treatment for a liver disease that is on track for approval later this year.

The deal values CymaBay at $32.50 per share, 27% higher than the stock’s close last Friday. That’s a relatively small takeout premium, but CymaBay shares have doubled in value since last fall on growing investor confidence in the company’s lead drug and speculation that the company could be acquired.

CymaBay’s drug, called seladelpar, is being developed for the treatment of primary biliary cholangitis, or PBC, a type of liver disease mainly affecting women that causes decreased liver function, and debilitating itching and fatigue. Progression of PBC to more advanced stages increases the risk of liver-related death.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： George Santos makes 1st court appearance after pleading not guilty to 13 counts
Next article： How to pay for weight loss drugs and save Medicare

focus

WSS

How to save PrEP access — and even expand it

As biotech industry slumps, bioscience job market is upside down

Rep. Raul Ruiz on the physician shortage and more

23andMe had bad news about my health. I wish a person had delivered it

Dobbs anniversary: the lost opportunity of abortion as health care

Apple is now the first public company to be valued at $3 trillion

focus

focus

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

30 years of 'Listening to Prozac'

At least 13 dead in Texas as scorching temps continue

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Dobbs anniversary: the lost opportunity of abortion as health care

The cancer drug shortage isn’t new — and neither are the solutions

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Heart attack and stroke risk calculators need revising

Anesthesiologist group: stop taking Ozempic before surgery

CDC director unscathed in first congressional testimony

explore

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Novavax promises a turnaround & Lilly roils the obesity market

CDC director unscathed in first congressional testimony

Guidelines to prevent youth baseball injuries need more muscle

Flagship Pioneering launches a new biotech in two countries

In age of alternative facts, a scholarly course on calling out crap

Wikipedia

focus

focus

hotspot